Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 13/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.34 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8046080 | 0.88 | MC4R (0.39) | MC4RTBXAS1SLC2A1 | |
| SCHEMBL8036015 | 0.85 | MC4R (0.49) | MC4R | |
| SCHEMBL8046141 | 0.84 | MC4R (0.39) | MC4RTBXAS1 | |
| SCHEMBL8035790 | 0.81 | MC4R (0.37) | MC4RTBXAS1SLC2A1 | |
| SCHEMBL8034742 | 0.81 | MC4R (0.37) | MC4RSLC2A1 | |
| SCHEMBL11929582 | 0.81 | MC4R (0.39) | MC4RTBXAS1SLC2A1 | |
| SCHEMBL8037842 | 0.78 | SLC2A1 (0.37) | MC4RSLC2A1 | |
| SCHEMBL8022888 | 0.77 | MC4R (0.49) | MC4R | |
| SCHEMBL12990148 | 0.76 | MC4R (0.47) | MC4R | |
| SCHEMBL8025981 | 0.76 | MC4R (0.47) | MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324036-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-12-23 | — | — | US | disclosed |
| WO-2009080291-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324036-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | MC4R, MC5R, MC3R | MC4R 1/4885TBXAS1 3787/4885GRIN2D 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.